Custom robotic workstation automates company’s broad portfolio of biology assays for academia, biotech, and pharma

定制机器人工作站为学术界、生物技术和制药公司自动化了公司广泛的生物学检测组合

Meets growing need for autonomous tools that boost throughput and reproducibility

满足对提高吞吐量和可重复性的自主工具的日益增长的需求

Provides customers with verified and automated workflows

为客户提供经过验证的自动化工作流程

Merck, a leading science and technology company, and Opentrons Labworks, Inc., a leader in lab automation and accessible robotics, announced a multi-year agreement to automate assay kits on a custom Opentrons Flex

领先的科技公司默克公司和实验室自动化和无障碍机器人领域的领导者Opentrons Labworks，Inc.宣布了一项多年协议，将在定制的Opentrons Flex上自动化检测试剂盒

®

®

workstation.

工作站。

Scientists and engineers will collaborate to develop and verify platform workflows utilizing Merck’s broad offering of automation-enabled assays. Together, the custom workstation and automation-enabled assays will deliver increased consistency and higher throughput by reducing manual processing and repetitive tasks with a user-friendly robotic system..

科学家和工程师将合作开发和验证平台工作流程，利用默克公司广泛提供的自动化检测。。。

“Our customers are prioritizing tools and technologies that improve reproducibility and productivity, allowing them to focus on more complex tasks that take their science further, faster,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck. “Our partnership with Opentrons reinforces our focus to automate and digitalize the lab - supporting scientists at all stages with tools that can increase efficiency, safety, and success rates of delivering new potential therapeutics.”.

默克生命科学业务科学与实验室解决方案负责人让·查尔斯·沃思（Jean Charles Wirth）表示：“我们的客户正在优先考虑提高可重复性和生产力的工具和技术，使他们能够专注于更复杂的任务，从而使他们的科学更进一步、更快。”。“我们与Opentrons的合作加强了我们对实验室自动化和数字化的关注，支持科学家在各个阶段使用能够提高提供新的潜在疗法的效率，安全性和成功率的工具。”。

Customers can place orders for workstations and assay kits from Merck starting mid-2025. Applications will include broad workflows across protein sample preparation, molecular, cell, and other biochemical and chemistry workflows launching throughout the length of the agreement.

从2025年年中开始，客户可以从默克公司订购工作站和检测试剂盒。应用程序将包括在整个协议期间启动的蛋白质样品制备，分子，细胞以及其他生化和化学工作流程的广泛工作流程。

“Part of our commitment to making lab automation as accessible as possible is finding partners who share a similar vision,” said Jonathan Brennan-Badal, CEO of Opentrons. “Merck Life Science is a proven leader in terms of the breadth and quality of products they offer for pharmaceutical development and manufacturing, and we’re excited to combine that with our ability to provide world-class automation, service and support.”.

Opentrons首席执行官乔纳森·布伦南·巴达尔（JonathanBrennanBadal）表示：“我们致力于尽可能实现实验室自动化的一部分是寻找具有类似愿景的合作伙伴。”。“默克生命科学公司在为药物开发和制造提供的产品的广度和质量方面是公认的领导者，我们很高兴将其与我们提供世界级自动化、服务和支持的能力相结合。”。

By combining the automation expertise and service excellence of Opentrons with the powerful R&D, supply chain, and quality systems of Merck we will deliver reliable products streamlining research from sample prep to analysis for immunodetection, protein research, enzyme technology, genome editing, omics research, pharmaceutical development, service and testing and cell culture..

通过将Opentrons的自动化专业知识和卓越服务与默克强大的研发、供应链和质量体系相结合，我们将提供可靠的产品，简化从样品制备到免疫检测分析、蛋白质研究、酶技术、基因组编辑、组学研究、药物开发、服务和测试以及细胞培养的研究。。

This adds to Merck’s existing Biology innovations to increase Life Science lab productivity, like the Millicell

这增加了默克公司现有的生物学创新，以提高生命科学实验室的生产力，如Millicell

®

®

DCI Digital Cell Imager that allows for accelerated cell culture analysis with an intuitive interface while also adding to the company’s commitment to provide next-generation biology solutions such as their recent acquisition of HUB Organoids Holding B.V.

DCI数字细胞成像仪，可以通过直观的界面加速细胞培养分析，同时也增加了公司提供下一代生物学解决方案的承诺，例如最近收购HUB Organoids Holding B.V。